Understanding of the molecular basis of therapy for osteoporosis

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K20856
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: General pharmacology; Pharmacology in pharmacy
• Research Institution: Tohoku University
• Principal Investigator: Saito Masaki 東北大学, 医学系研究科, 助教 (50400271)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 副甲状腺ホルモン受容体 / 4.1Gタンパク質 / Tctex-1 / 骨芽細胞分化 / アデニル酸シクラーゼ / サイクリックAMP

Outline of Final Research Achievements

Parathyroid hormone (PTH) is the only medicine, which promotes osteoblast differentiation and osteogenesis. However, mechanisms of the differentiation and osteogenesis have been unclear. In the present study, I found that 4.1G and Tctex-1, both of which were identified as interacting proteins to PTH receptor, suppressed and increased PTH receptor-mediated Gs/adenylyl cyclase/cyclic AMP (cAMP) signaling pathway, respectively. On the other hand, I also found that 4.1G promoted osteoblast differentiation induced by ascorbic acid/β-glycerophosphate, suggesting that 4.1G regulates osteoblast differentiation by different mechanisms from the suppression of cAMP production.

Free Research Field

分子薬理学